Methylation of tumour suppressor genes associated with thyroid cancer.
Adaptor Proteins, Signal Transducing
/ genetics
Adolescent
Adult
Aged
Cell Line, Tumor
DNA Methylation
DNA-Binding Proteins
/ genetics
Female
Gene Expression
Genes, Tumor Suppressor
/ physiology
Humans
LIM Domain Proteins
/ genetics
Male
Middle Aged
Prognosis
Promoter Regions, Genetic
Repressor Proteins
/ genetics
Thyroid Neoplasms
/ genetics
Tumor Protein p73
/ genetics
Young Adult
Thyroid cancer
epigenetics
promoter methylation
tumour suppressor genes
Journal
Cancer biomarkers : section A of Disease markers
ISSN: 1875-8592
Titre abrégé: Cancer Biomark
Pays: Netherlands
ID NLM: 101256509
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
23
4
2019
medline:
23
11
2019
entrez:
23
4
2019
Statut:
ppublish
Résumé
Thyroid carcinoma is the most common endocrine malignancy worldwide. Changes in DNA methylation can cause silencing of normally active genes, especially tumour suppressor genes (TSG) or activation of normally silent genes. The aim of this study is to evaluate the degree of promoter methylation for a panel of markers for thyroid neoplasms and to establish their relationship with thyroid oncogenesis. To generate a comprehensive DNA methylation signature of TSGs involved in thyroid neoplasia, we use Human TSG EpiTect Methyl II Signature PCR Array-Qiagen for 24 samples (follicular adenomas and papillary thyroid carcinomas) compared with normal thyroid tissue. We extended the evaluation for three TSGs (TP73, WIF1, PDLIM4) using qMS-PCR. Statistical analysis was performed with GraphPad Prism. We noted four important genes NEUROG1, ESR1, RUNX3, MLH1, which presented methylated promoter in tumour samples compared to normal. We found new characteristic of thyroid tumours: methylation of TP73, WIF1 and PDLIM4 TSGs, which can contribute to thyroid neoplasia. A significant correlation between BRAF V600E mutation and RET/PTC rearrangements with TIMP3 and CDH13, RARB methylation, respectively was observed. TSGs promoter hypermethylation is a hallmark of cancer and a test that uses methylation quantification method is suitable for diagnosis and prognosis of thyroid cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Thyroid carcinoma is the most common endocrine malignancy worldwide. Changes in DNA methylation can cause silencing of normally active genes, especially tumour suppressor genes (TSG) or activation of normally silent genes.
OBJECTIVE
OBJECTIVE
The aim of this study is to evaluate the degree of promoter methylation for a panel of markers for thyroid neoplasms and to establish their relationship with thyroid oncogenesis.
METHODS
METHODS
To generate a comprehensive DNA methylation signature of TSGs involved in thyroid neoplasia, we use Human TSG EpiTect Methyl II Signature PCR Array-Qiagen for 24 samples (follicular adenomas and papillary thyroid carcinomas) compared with normal thyroid tissue. We extended the evaluation for three TSGs (TP73, WIF1, PDLIM4) using qMS-PCR. Statistical analysis was performed with GraphPad Prism.
RESULTS
RESULTS
We noted four important genes NEUROG1, ESR1, RUNX3, MLH1, which presented methylated promoter in tumour samples compared to normal. We found new characteristic of thyroid tumours: methylation of TP73, WIF1 and PDLIM4 TSGs, which can contribute to thyroid neoplasia. A significant correlation between BRAF V600E mutation and RET/PTC rearrangements with TIMP3 and CDH13, RARB methylation, respectively was observed.
CONCLUSIONS
CONCLUSIONS
TSGs promoter hypermethylation is a hallmark of cancer and a test that uses methylation quantification method is suitable for diagnosis and prognosis of thyroid cancer.
Identifiants
pubmed: 31006665
pii: CBM182265
doi: 10.3233/CBM-182265
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
DNA-Binding Proteins
0
LIM Domain Proteins
0
PDLIM4 protein, human
0
Repressor Proteins
0
TP73 protein, human
0
Tumor Protein p73
0
WIF1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM